Portola Pharmaceuticals (NASDAQ:PTLA)

CAPS Rating: 5 out of 5

Caps

How do you think PTLA will perform against the market?

Add Stock to CAPS Watchlist

All Players

106 Outperform
0 Underperform
 

All-Star Players

35 Outperform
0 Underperform
 

Wall Street

1 Outperform
0 Underperform
 

Top PTLA Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

TMFEBCapital (90.24)
Submitted April 05, 2017

The potential to vie for market share from Lovenox in acute medically ill patients ($3 bn sales at peak) suggests an OK on betrixaban makes this company's upside opportunity big. An approval of AndexXa opens up hundreds of millions in potential sales… More

usubanas (99.58)
Submitted August 07, 2014

I'm the only underperform, really?

PTLA VS S&P 500 (SPY)

Fools bullish on PTLA are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about PTLA.

Recs

0
Member Avatar Capitalism (95.09) Submitted: 6/1/2018 12:10:27 PM : Outperform Start Price: $40.26 PTLA Score: +1.80

Richard Marzouka (SA) pick

Recs

1
Member Avatar TMFEBCapital (90.24) Submitted: 4/5/2017 11:14:17 AM : Outperform Start Price: $39.02 PTLA Score: -10.70

The potential to vie for market share from Lovenox in acute medically ill patients ($3 bn sales at peak) suggests an OK on betrixaban makes this company's upside opportunity big. An approval of AndexXa opens up hundreds of millions in potential sales associated with reversing factor Xa anticoagulants (currently, there are no FDA approved antidotes). This is a pivotal year for the company, and rejections could cause shares to plummet, but an OK on these two drugs could also make this stock a lottery ticket. Risk tolerant investors only.

Recs

0
Member Avatar brendanf (< 20) Submitted: 3/6/2017 1:20:59 AM : Outperform Start Price: $38.26 PTLA Score: -8.21

Blockbuster drug potential. Backing from huge drug companies, manufacturing drugs that are needed ASAP in the marketplace. Stock was touching $50 before the FDA postponed the approval for 6 months. Approval is back on track and should be achieved by Q3/Q4 2017. Great value here and still room to grow.

Leaderboard

Find the members with the highest scoring picks in PTLA.

Score Leader

mrefranklin

mrefranklin (87.52) Score: +206.78

The Score Leader is the player with the highest score across all their picks in PTLA.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
odocoileus 62.43 10/20/2016 Outperform 5Y $19.00 +117.95% +29.31% +88.64 0 Comment
TMFang4apples 46.59 8/19/2016 9/26/2017 Outperform 5Y $19.63 +110.95% +26.46% +84.49 0 Comment
jandq 68.06 8/22/2016 Outperform 5Y $19.62 +111.06% +26.71% +84.35 1 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. 1dms 79.13 10/21/2016 Outperform 5Y $19.39 +113.56% +29.63% +83.94 0 Comment
bwalk037 69.35 8/29/2016 9/19/2017 Outperform 1Y $20.50 +101.98% +26.63% +75.34 0 Comment
ACPdiddy 24.96 3/24/2016 Outperform 5Y $20.56 +101.41% +36.37% +65.04 0 Comment
steved09 65.19 10/10/2016 Outperform 3Y $21.50 +92.60% +27.95% +64.66 0 Comment
princeofprice 54.83 5/19/2014 Outperform 5Y $20.07 +106.33% +47.35% +58.98 0 Comment
OakMC 58.00 7/18/2016 Outperform 5Y $22.16 +86.87% +28.16% +58.70 0 Comment
lancealot 88.05 7/18/2016 Outperform 5Y $22.16 +86.87% +28.16% +58.70 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackBernstein 89.84 6/28/2013 Outperform NS $25.08 +65.11% +72.17% -7.06 0 Comment

Featured Broker Partners


Advertisement